August 12, 2022
Authored and Edited by Angeline L. Premraj; Caitlin E. Fowler; Esther H. Lim
In Thaler v. Vidal, No. 21-2347 (Fed. Cir. Aug. 5, 2022), the Federal Circuit affirmed the district court’s grant of summary judgment because an “inventor” must be a natural person.
Thaler filed two patent applications that named an Artificial Intelligence (AI) program as the sole inventor. Thaler’s applications were deemed incomplete because they lacked a valid inventor. Thaler’s petition to the PTO director was denied on the grounds that a machine cannot qualify as an inventor. Thaler appealed the PTO’s decision to the Eastern District of Virginia, which granted the PTO’s motion for summary judgment concluding that an “inventor” must be an “individual” and that the individual must be a natural person.
In affirming the district court’s decision, the Federal Circuit found that the Patent Act unambiguously requires that inventors be human beings. The Court explained that the Patent Act provides that inventors are “individuals,” which is ordinarily understood to mean a natural person. See §§ 100(f)-(g), 115. The Court further explained that nothing in the Patent Act demonstrates that Congress intended to deviate from this default meaning. The Court rejected Thaler’s reliance on other sections of the Patent Act, namely 35 U.S.C. §§ 101, 103, and 271, because these sections do not trump the provision that specifically addresses who may be an inventor. The Court also found unpersuasive that South Africa has granted patents with DABUS as an inventor because that foreign patent office was not interpreting the Patent Act.
Copyright © 2022 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026
May 26, 2026
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.